ERBB2 and neoplasm: Rosewell et al. pre-treated HNSCC with engineered binary oncolytic adenovirus (CAd) that can express programmed cell death-ligand 1 (PD-L1) blockade antibodies and cytokines, thereby improving the anti-tumor effect of HER2-targeting CAR-T cells [42].